China's National Medical Products Administration (NMPA) and National Healthcare Security Administration have launched joint inspections of medical institutions and pharmaceutical wholesalers in the Inner Mongolia Autonomous Region and Shanxi Province following the identification of suspicious activity through drug traceability code screening.